Results 141 to 150 of about 3,096 (189)

Clinical and Molecular Predictors of Response and Survival in Patients with Urothelial Carcinoma Treated with Enfortumab Vedotin: A Systematic Review and Meta-analysis. [PDF]

Eur Urol Open Sci
Altenni M, Fehérvári P, Hoferica J, Hegyi P, Ács N, Fazekas T, Vargha J, Grünwald V, Darr C, Riesz P, Nyirády P, Szarvas T.   +11 more
europepmc   +1 more source

Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study. [PDF]

Cancer Med
Nizam A, Nguyen CB, Li J, Zabor EC, Msaouel P, Jiang CY, Alhalabi O, Oh E, Davidsohn MP, Epstein IB, Bakaloudi DR, Talukder R, Jindal T, Taylor AK, Glover MJ, Khaki AR, Lemke E, Mabey H, Abuqayas B, Jang A, Brown JR, Evans ST, Pywell C, Basu A, Bilen MA, Barata PC, Zakharia Y, Milowsky MI, Kilari D, Hoimes CJ, Shah SA, Emamekhoo H, Davis NB, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS.   +38 more
europepmc   +1 more source

One Man's Meat Is Another Man's Poison: High Incidence of Severe Cutaneous Drug Reactions Induced by Enfortumab Vedotin. [PDF]

Eur Urol Open Sci
Pan Y, Yu R, Huang H, Chen X, Gou X, Chen A.   +5 more
europepmc   +1 more source

Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis [PDF]

Di Maio, Massimo
core   +1 more source

Assessing the patient reported outcomes (PROs) of enfortumab vedotin plus pembrolizumab versus platinum-based chemotherapy in patients with advanced urothelial carcinoma in the EV-302 study. [PDF]

Transl Androl Urol
Okobi TJ, Vaishampayan N, Subramanya D, Tagawa ST.   +3 more
europepmc   +1 more source

The patients have spoken: how does enfortumab vedotin impact quality of life? [PDF]

Transl Androl Urol
Brown JR.
europepmc   +1 more source

Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort. [PDF]

Eur Urol Open Sci
Fiala O, Grillone F, Fujita K, Grande E, Giannatempo P, Taha T, Myint ZW, Büttner T, de Liaño AG, Kanesvaran R, Facchini G, Yano A, Formisano L, Poprach A, Conteduca V, Pirshtuk A, Studentova H, Kopecky J, Sammarco E, Mota A, Incorvaia L, Nasso C, Maffezzoli M, Ghose A, Soares A, Buti S, Marques Monteiro FS, Massari F, Gupta S, Bellmunt J, Banna GL, Santoni M.   +31 more
europepmc   +1 more source

Pembrolizumab and Enfortumab Associated Bullous Pemphigoid [PDF]

Chi, Dorcas
core  

Enfortumab Vedotin-Induced Toxic Epidermal Necrolysis in Metastatic Urothelial Carcinoma Complicated by Severe Gastrointestinal Bleeding. [PDF]

IJU Case Rep
Matsuyama A, Kato T, Kawase R, Kobayashi M, Momota A, Tsunoda Y, Yamaguchi A, Hirabayashi H, Suzuki S, Kato M.   +9 more
europepmc   +1 more source

Steroid Premedication Impact on Efficacy and Cutaneous Toxicity of Enfortumab Vedotin for Advanced Urothelial Carcinoma. [PDF]

In Vivo
Furubayashi N, Mochida M, Kijima A, Fujimoto Y, Nakamura M, Negishi T.   +5 more
europepmc   +1 more source